Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride and finasteride mesotherapy may have fewer side effects like erectile dysfunction and libido loss compared to oral treatments, but it's less effective and more costly. Few people discuss it, and experiences with mesotherapy are limited.

HopeMed is upset with Absci for allegedly using misleading information about HMI-115's performance compared to ABS-201. HopeMed plans to take legal action to protect its confidential data and trade secrets.

Dutasteride may cause retrograde alopecia, with users experiencing hair loss on the neck and sides. Some users report slight improvement in hair thickness on top but no overall regrowth.

A 15-year-old experiencing hair loss and anxiety is using minoxidil and microneedling but is advised against starting finasteride or dutasteride due to age. The discussion emphasizes consulting a doctor, considering hormonal evaluations, and exploring non-medication coping strategies.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

The conversation discusses concerns about body dysmorphia related to hair loss, with some users expressing frustration over posts claiming treatments like finasteride and dutasteride are ineffective or harmful despite minimal hair loss. It emphasizes the importance of early treatment with medications like finasteride and minoxidil for those experiencing hair loss.

The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

A 19-year-old has been experiencing diffuse thinning since age 16 and has not seen improvement despite using minoxidil, finasteride, dutasteride, and other treatments. Suggestions include increasing dutasteride dosage, using RU58841, and considering topical treatments or a hair transplant.

A 19-year-old male is experiencing accelerated hair recession after two months on oral Dutasteride, despite no noticeable shedding, while also using topical Minoxidil and Finasteride. He is unsure if the treatment is effective and is unable to access RU58841.

A user shared their 8-month progress using dutasteride 0.5 mg and oral minoxidil 2.5 mg for hair loss, expressing disappointment with the results and considering increasing the dosage. Other users advised patience, suggesting that improvements can continue over time, and recommended consulting a dermatologist before making changes.

A 29-year-old male with androgenic alopecia was treated with oral Dutasteride, oral Minoxidil, and injectable Dutasteride, showing progress in 9 months. Some users believe Dutasteride mesotherapy is unnecessary and question its effectiveness compared to topical applications.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

The user switched from finasteride to dutasteride after 1.5 years without results. They are hopeful the new treatment will work.

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

Finasteride and minoxidil remain the primary treatments for hair loss, with dutasteride being a more potent alternative. New treatments like VDPHL01 and topical antiandrogens are in development.

The conversation discusses a hair loss treatment regimen involving high doses of dutasteride, finasteride, and minoxidil, with concerns about safety and potential side effects. Users advise against the excessive use of these medications, suggesting more moderate approaches and consulting a doctor.

A user experienced significant hair regrowth using dutasteride without side effects, starting with finasteride and not using minoxidil or dermarolling. They attributed success to a unique genetic response to DHT blockers but did not share their full regimen, frustrating others.

The conversation is about a user considering reducing their dutasteride dose due to side effects like lower libido and watery semen. They plan to use dutasteride mesotherapy every three months to maintain hair while reducing systemic DHT suppression.

A 22-year-old male has been using Dutasteride 0.5 mg every other day and Minoxidil 5% daily since December 2024 for hair loss, with no side effects reported. Users discuss varying dosages of Dutasteride, with some expressing concerns about higher doses.

OP has been using spironolactone and minoxidil for 3 years with slow hair growth results, possibly affected by vaping. Users suggest adding microneedling, hair serum, dietary changes, and checking spironolactone dosage for better results.

A user experienced a "watery belly" and cellulite after starting finasteride, despite maintaining a disciplined fitness routine. Others suggest checking hormone levels, as changes in DHT and estrogen could affect fat metabolism, but age might also be a factor.

Dermastamps are preferred over dermarollers for microneedling due to precision and reduced risk of scarring. Dermastamps allow for controlled, vertical needle entry, while dermarollers may cause more damage with sideways needle entry.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Using Dutasteride once a week may have similar effects to daily Finasteride with potentially fewer side effects. Users report varying experiences, with some noticing improved hair and fewer side effects compared to Finasteride.

The user is considering increasing their dose of Dutasteride from 0.5 mg to 2.5 mg while using Minoxidil, DermaRoll, and other treatments for hair regrowth after multiple hair transplants. Many responses suggest accepting baldness or using a hair system instead of continuing with medications.

A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.